A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene
BeiGene
Basilea Pharmaceutica
Monteris Medical
Boston Scientific Corporation
PharmaEngine
PharmaEngine
Dynavax Technologies Corporation
Tetra Bio-Pharma
Celgene
Actelion
GlaxoSmithKline
Merck Sharp & Dohme LLC
GlaxoSmithKline
Boehringer Ingelheim
Agennix
Genmab
Bradmer Pharmaceuticals Inc.
Sanofi
Eli Lilly and Company
AstraZeneca